Wegovy Approved in the UK: What the Licence Actually Covers

What exactly is Wegovy approved for in the UK?

Wegovy is the brand name for semaglutide made by Novo Nordisk. Its core approval covers weight management in adults: a BMI of 30 or above, or a BMI between 27 and 29.9 where at least one weight-related health condition is present. That condition might be type 2 diabetes, obstructive sleep apnoea, high blood pressure or raised cholesterol, among others. The medicine is used alongside a reduced-calorie diet and increased physical activity, it is not a standalone fix, and prescribers assess the full clinical picture before recommending it.

Beyond weight management, the UK licence has grown. Wegovy is separately authorised for reducing the risk of major cardiovascular events in eligible adults. Then, on 3 July 2026, the MHRA granted conditional approval for a further indication: MASH (metabolic dysfunction-associated steatohepatitis), a form of fatty liver disease with moderate-to-advanced fibrosis. That approval was the first of its kind for any medicine in this condition. The weight-loss approval specifically remains the most widely relevant for people exploring Wegovy as a treatment option, and it is the indication through which a private prescriber at a regulated pharmacy would work.

Semaglutide in other forms (Ozempic as an injection, Rybelsus as a tablet) carries a licence for type 2 diabetes, not weight management. The distinction matters practically and legally. You can read more about semaglutide's weight-loss approval status across its different brands and forms.

How did the higher-dose and oral approvals change things?

The original Wegovy injection topped out at a 2.4mg weekly maintenance dose. Clinical trial data showed around 15% average body-weight reduction over 68 weeks at that dose, a result published in the New England Journal of Medicine in the STEP 1 trial. That was already a meaningful figure, but researchers and clinicians knew some patients needed more.

The MHRA approved a 7.2mg maintenance dose in January 2026. A dedicated single-dose pen for 7.2mg followed on 14 April 2026, designed so patients take one weekly injection rather than managing three separate pens. Trials at the higher dose reported around 20.7% average weight loss over 72 weeks, bringing Wegovy's ceiling much closer to that of tirzepatide. The starting dose stays the same (0.25mg) and titration up to 7.2mg is managed by the prescriber over time.

Then came the tablet. On 11 June 2026, the MHRA approved oral semaglutide (Wegovy tablets) for weight management, the first oral GLP-1 medicine licensed for this purpose anywhere in Europe. The UK was first. The OASIS 4 phase-3 trial, which ran for 64 weeks, reported an average weight reduction of around 13.6% versus approximately 2.4% on placebo. Among participants who adhered fully to treatment, the figure was closer to 17%. If you want to understand how Wegovy works across its different forms, that page pulls together the practical detail.

Who can actually access it, NHS versus private prescription?

NICE recommended Wegovy for NHS use in 2023 under technology appraisal TA875, but with tight conditions: a maximum treatment duration of two years, use within a specialist weight management service with multidisciplinary support, a BMI of 35 or above (or 30 to 34.9 in certain circumstances), and at least one weight-related comorbidity. Ethnic-background thresholds are typically 2.5 kg/m² lower. NHS waiting lists for specialist services are long in most areas, and not everyone meets the criteria.

Private treatment through a regulated pharmacy operates under the medicine's licensed eligibility directly: BMI 30 or above, or 27 or above with a qualifying condition. There is no two-year cap, no waiting list, and no referral required, though a prescriber still makes the clinical call. It is worth knowing that some people find it useful to time a private start around a predictable point in the month; the cost context is easier to plan when you know exactly what is included. For a clear breakdown of what private treatment costs, the Wegovy cost page sets out what charges typically cover and what to watch for.

Scotland, Wales and Northern Ireland apply different access criteria through their own health systems. For anything NHS-specific, NICE's technology appraisal TA875 is the primary reference.

What are the side effects the MHRA has flagged since approval?

Gastrointestinal effects dominate the side-effect profile: nausea, vomiting, diarrhoea and constipation are the most common, and they tend to peak in the days following a new dose or increase. Most people find they settle within a couple of weeks. Stomach upset on Wegovy is one of the questions our prescribers hear most often, and there is practical guidance available on managing it.

The MHRA also issued a Drug Safety Update in January 2026 drawing attention to acute pancreatitis across GLP-1 medicines, it is an infrequent but potentially serious effect. Severe stomach pain that spreads to the back, with or without vomiting, warrants urgent medical attention rather than waiting to see if it settles. Gallbladder symptoms, injection-site reactions and dizziness are also documented. Wegovy carries a Black Triangle (▼) designation, meaning it is under additional MHRA monitoring and any suspected side effects can be reported at the MHRA's Yellow Card scheme.

Wegovy is not approved for use in pregnancy, breastfeeding, or in anyone trying to conceive. It is not licensed for those under 18. Existing medical conditions (particularly a history of pancreatitis or medullary thyroid carcinoma) require careful prescriber review before treatment begins. The age-related approval criteria page covers the under-18 question directly for those searching specifically on that point.

If Wegovy looks like it might suit your situation, a clinician at our pharmacy can assess your eligibility properly. Start your free consultation and a GPhC-registered prescriber will review your answers the same day.